NeuroSense to Present New Data on PrimeC for ALS at AD/PD 2026 Conference

NeuroSense Therapeutics will present new data on PrimeC, a therapy for amyotrophic lateral sclerosis (ALS), at the AD/PD 2026 conference. Dr. Christian Lunetta will present findings from the Phase 2b PARADIGM trial and insights into disease mechanisms and treatment effects. The data will inform the design of the global Phase 3 PARAGON trial, currently in development. The presentation will review key clinical and biomarker findings from the PARADIGM trial and provide an important scientific foundation for advancing therapeutic development in ALS.